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1. Introduction 
Fragile X syndrome (FraX) was first described by Dr. Martin and Dr. Bell in 1943, in families 
with both males and females affected by sex-linked mental retardation (1) and was later 
identified as the most common cause of inherited mental retardation (2-4). The prevalence of 
the Fragile X syndrome has been estimated in 1 out of 2,500 males and 1 out of 4,000 females 
(5, 6). 
In addition of moderate to severe mental retardation, FraX individuals exhibit 
macroorchidism, an elongated face (7), long ears, connective tissue dysplasia, hyperactivity, 
autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity 
(8,9). Typical neuropathological features of the FraX are long, thin, and tortuous appearance 
of cortical dendritic spines (10,11), increased intracranial volume (12), enlarged ventricles, 
increased volumes of selective subcortical gray matter regions, decreased size of the 
posterior cerebellar vermis (13), and an altered glucose metabolism (14).  
The syndrome was named after identification of a fragile site that was located in the long 
arm of the X chromosome, detected by cytogenetic testing in a cell culture medium deprived 
of folic acid (15). The Fragile X mental retardation 1 (FMR1) gene was linked to that region 
(Xq27.3) and a dynamic CGG repeat expansion mutation was determined to be the cause of 
the syndrome (16). A full-mutation with more than 200 CGG repeats, causes methylation of 
the FMR1 gene and consequently leads to a transcriptional silencing of the gene and the 
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absence of the FMRP protein(17). It has been established as a normal range of CGG triplets 
between 6 and 55 repeats, and a CGG expansion over this range is considered abnormal. An 
unstable pre-mutation allele consists of more than 55 CGG repeats which results in 
increased levels of the mRNA in order to keep the normal level of the FMRP protein. This 
may be due to a compensatory mechanism derived from a translation problem of the 
premutated mRNA (18). A new syndrome has been described in males and females older 
than 50-60 years of age, carrying a premutated allele it is known as Fragile X premutation 
tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder with core features of action 
tremor and cerebellar gait ataxia. Frequent associated findings include parkinsonism, 
executive function deficits, neuropathy, and dysautonomia. It is caused by increased levels 
of FMR1-mRNA leading toneurotoxicity in the brain (19).  
The physiological effects of FMRP are still not well understood and the mechanisms that 
explain the pathogenesis of this syndrome remain unclear. FMRP is a mRNA binding 
protein (20), which is involved in the translational regulation of a specific set of mRNAs (21). 
FMR1 is a member of a gene family including FXR1 and FXR2. These three genes have very 
strong homology, overlapping expression patterns in neuronal cells, and they form homo 
and heterodimers. These features suggest that the differences between some of their 
physiological roles may be subtle (22). All three proteins function as mRNA binding 
proteins and they form complexes with additional proteins to transport target mRNA from 
the nucleus to the cytoplasm in microtubule-dependent movements that drive the 
complexes to the neurites in PC12 cells stimulated with nerve growth factor (23).  
FMRP is primarily observed in tissues of ectodermic origin and is highly expressed in the 
mouse adrenal medulla without co-expression of FXR1P and FXR2P, suggesting that FMRP 
may have a specific function in this tissue (24). The adrenal gland mainly secretes 
catecholamines (epinephrine, norepinephrine and dopamine) and glucocorticoids (cortisol). 
These hormones are involved in many essential metabolic functions in the body; in 
particular, they regulate the hypothalamus-pituitary-adrenal axis (HPA) that allows the 
organism to adapt to stressful situations (25). Adrenal activity in the postnatal period is 
essential for normal development of the HPA axis. There is evidence that FraX is associated 
with alterations in the action of the HPA axis (26, 27). Recently, abnormalities in 
glucocorticoids secretion in FraX individuals and in the FraX experimental model, Fmr1-
knockout mice, have been reported (28, 29). The main targets of glucocorticoids in the brain 
are the hippocampus, amygdala and cortex, with an active role in the adaptive response of 
the organism to stress processes, and an impact in the learning process and memory (spatial 
orientation, or declarative and spatial memory) (30, 31). Also, an abnormal catecholamine 
content has been demonstrated in the Fmr1-knockout mouse model (32).   
Recent studies indicate that the absence of FMRP changes the expression of many proteins 
such as those implicated in RhoGTPase signalling (GDI, RhoA), REDOX processes 
(Superoxide Dismutase, Glutathione peroxidase, SCD1, Pi3 Kinase) and neurotransmission 
(GabaA receptor or glucocorticoid receptor) (33,34). Our previous results indicate an excess 
of Rac1GTPase activation leading to NADPH oxidase-dependent activation and high levels 
of free radical production in the brain of the Fmr1-knockout mice. Moreover, an elevated 
oxidative stress and an alteration in antioxidant systems, including glutathione (GSH) 
decrease, are also observed in the Fmr1-knockout brain (35). It has been demonstrated that 
oxidative stress increases or acumulates selectively in CA3 and DG of the ventral 
hippocampus in psychiatric disorders. Such redox dysregulation alters stress and emotion-
related behaviours but leaves intact spatial abilities, indicating functional disruption of the 
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ventral but not dorsal hippocampus. Thus, a GSH deficit affects PV-IR interneuron's 
integrity and neuronal synchrony in a region- and time-specific manner, leading to 
behavioural phenotypes related to psychiatric disorders (36).  
The central nervous system (CNS) is highly sensitive to oxidative stress due to its specific 
anatomical and physiological characteristics. Neurons consume oxygen (O2) and produce 
ATP to maintain intracellular gradients of different ions (K+, Na+, Ca2+). Free radicals from 
oxygen and nitrogen (ROS and RNS) are involved in REDOX regulation of several protein 
functions such as Glutamate carriers or neurotransmitter receptors, and their increase leads 
to excitotoxicity processes that affect cellular functions, and provoke cellular death in the 
long-term (37). 
It is well known that REDOX regulation is involved in many important cellular mechanisms 
in neurons, astrocytes and microglia, such as the activation of MAPK cascade (mitogen 
activated protein kinase) (ERK/12, JNK1/2, p38MAPK), Ca2+ release and the activation of 
apoptotic processes (38-40). ROS produced by mitochondrial proteins or membrane proteins 
(like NADPH-oxidase activated by Rac1) have a role in physiological plasticity and may be 
required for normal cognitive functions (41). An excess of ROS, however, can induce 
harmful changes in cellular physiology. Cells can be protected from oxidation with 
antioxidant and detoxification processes, for example through the activation of the 
glutathione (GSH) system (42).  
Glutathione plays a critical role as an antioxidant, enzyme co-factor, the major redox buffer, 
and as neuromodulator in the central nervous system. Cysteine has itself neurotoxic effects 
mediated by free radical generation, increasing extracellular glutamate, and triggering over-
activation of N-methyl-D-aspartate (NMDA) receptors (43). GSH can also serve as a 
neuromodulator/neurotransmitter. GSH binds via its gamma-glutamyl moiety to NMDA 
receptors (44). GSH is thought to exert dual (agonistic/antagonistic) actions on neuronal 
responses mediated by NMDA receptors in the brain. GSH also serves as an endogenous 
NO reservoir by forming S-nitrosoglutathione (GSNO) (30). GSNO can release NO under 
certain conditions with biological effects, whilst GSNO has a protective effect in the brain 
under oxidative stress conditions (45). In addition, GSH is also required for cell proliferation 
and neuronal differentiation (46, 47).  
GSH deficiency has been implicated in neurodegenerative diseases. GSH is a tripeptide 
comprised of glutamate, cysteine, and glycine. Cysteine is the rate-limiting substrate for 
GSH synthesis within neurons. Most neuronal cysteine uptake is mediated by sodium-
dependent excitatory amino acid transporter (EAAT) systems, known as excitatory amino 
acid carrier 1 (EAAC1). Previous studies have demonstrated that EAAT is vulnerable to 
oxidative stress, leading to impaired functions (48).  
Oxidative stress can activate genes that encode the enzymes of antioxidant defence or 
transcription factors (NF-kB, AP1, Nrf2 y NF-AT) and many other structural proteins. The 
increase of Ca2+ in neurons can activate other enzymes including Kinase-C protein (PKC), 
phosphatase, phospholipase, nNOS, and xanthine oxidase (37). 
The normalization of oxidative stress can represent a new experimental target to treat 
disorders caused by an excessive production of free radicals. Oxidative stress has been 
found in neurological disorders, including epilepsy, Parkinson’s disorder, Down syndrome, 
Rett syndrome, Autism and Alzheimer’s disease (49). It has been demonstrated that 
neuronal damage due to oxidative stress, and/or hyperadrenergic states can be prevented 
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by treatment with free radical scavengers or specific compounds acting to prevent free 
radical production. It has also been shown that neuroprotective therapy prevents neuronal 
damage in neurodegenerative diseases like Parkinson's and Alzheimer's disease (50, 51). 
Nutrient deficiencies are common in attention-deficit hyperactivity disorder (ADHD). 
Supplementing the diet with minerals, vitamins, essential fatty acids omega-3 and omega-6, 
bioflavonoids, and phosphatidylserine improved ADHD symptoms of the disorder (52). 
Nutritional status is also related to intelligence, the treatment of mothers during pregnancy 
and lactation with eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA), examples 
of very-long-chain n-3 fatty acids, enhances the IQ in children (53). 
Currently, the pharmacological treatment used for the FraX has limited effects over the 
observed symptoms in patients. Stimulants of the central nervous system, such as 
methylphenidate, are used to treat hyperactivity, and antipsychotic drugs, such as 
Risperidone, are used to treat aggressive behaviour. Several drugs have been used to treat 
anxiety, such as Alprazolam or Lorazepam. Patients with epilepsy have been prescribed 
anticonvulsive drugs (54). In general, a drug or drug combinations are used to treat clinical 
symptoms; however there are no specific drugs to prevent the appearance of the disorder.   
Recent experiments in animal models introduce a new hypothesis for a specific treatment of 
the disorder using the antagonists of glutamate receptors (55, 56). It has been shown that 
some features in FraX mice can be normalized by the genetic deletion of the metabotropic 
glutamate receptor 5 (mGlur5) gene (57). Recent studies have identified ROS as downstream 
signalling molecules of group I mGluRs activation (58). Furthermore, a previous study has 
also demonstrated that a double knockout of the genes coding for FMRP and the p21-
activated kinase proteins prevent the FraX phenotype (59). These new findings are opening 
a new path for therapeutic research in the Fragile X Syndrome.  
Altered glucocorticoid secretion observed in FraX individuals might contribute to the loss of 
neurons in the hippocampus demonstrated through autopsies. Neuronal loss and the excess 
of cortisol may be related to hyperactivation of glucocorticoid receptors in the hippocampus 
and other brain areas such as amygdala and cortex (60). The long lasting activation of 
glucocorticoid receptors during development is known to affect the proliferation of 
neuronal precursors and increase the activation of glial cells, such as astrocytes (61). 
Furthermore, an altered adrenal secretion can produce an imbalance in brain oxidative 
stress that will lead to lipid and protein oxidation in the cell membranes. These changes 
alter the correct function of the synapses between neurons, affecting learning and behaviour, 
and in the long term will lead to intellectual impairment (62, 63).  
High-dose vitamin E supplementation may improve insulin action and decrease plasma 
fasting insulin and glucose levels by decreasing cellular oxidant stress, altering membrane 
properties, and decreasing inflammatory activity (64). Increased vitamin E intake may 
enhance the endogenous cellular antioxidant defence system and reduce levels of ROS that 
are produced by mitochondria. Vitamin E can also act at the cellular level independently of 
its antioxidant activity and may potentially contribute to improved insulin action through 
the inhibition of protein kinase C (65); the decrease of intracellular levels of diacylglycerol 
(66) and the activation of insulin substrate protein-1 (67). 
Vitamin E has also been used in children; most of the clinical data available are for ǂ-
tocopherol or tocopherol esters, such as ǂ-tocopheryl acetate. Its use is well documented in 
diseases such as abetalipoproteinemia (68), cystic fibrosis (69–71), ǃ-thalassemia, sickle cell 
anemia (72), inborn metabolism errors (73), epidermolysis bullosa (74), glucose-6 phosphate 
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dehydrogenase deficiency (75), and focal segmental glomerulosclerosis (76). Many studies 
do not state the rationale for dose calculation, and dosing regimens are not evaluated 
systematically. In children with cystic fibrosis, the doses differed among the studies: 5.5–47.4 
IU kg−1 day−1, 5–10 mg kg−1 day−1, and 50–100 IU/day (77, 78). 
Vitamin C has also been widely used in sick children; most of the clinical data available are 
for ascorbic acid or antioxidant combinations. Its use is well documented in diseases such as 
aphtous stomatitis (79), infant burns (80), Attention Deficit Hyperactivity Disorder (81) and 
hyperlipidemia and arterioscleroses (82). An oral dosage of 2000 mg/m(2)/day of Ascorbate 
may modulate the generation of reactive oxygen species and augment neutrophil apoptosis, 
which could prevent neutrophil-mediated inflammation in children (79). A 12-month high-
dose (30 mg/kg/day) trial of oral ascorbic acid was reported to be safe and well tolerated in 
children (2-16 years) (83). Vitamin C was also administered as it enhances the regeneration 
of oxidized vitamin E. Kinetic analysis and studies of vitamin E regeneration in a protein-
denaturing system revealed that ascorbate regenerates vitamin E by a nonenzymic 
mechanism, whereas glutathione regenerates vitamin E enzymatically. It was suggested that 
a significant interaction occurs between water- and lipid-soluble molecules at the 
membrane-cytosol interface and that vitamin C may function in-vivo to repair the 
membrane-bound oxidized vitamin E (84, 85). 
2. Methods and design 
We have designed a clinical trial to evaluate the effects of an antioxidant combination of 
ascorbic acid and alpha-tocopherol on the clinical condition of patients with FXS. The study 
includes patients from 6 years up to the age of 18 diagnosed with FXS; this limit was chosen 
as it is at this age when a decline in hyperactivity and behavioural symptoms may occur. 
The minimum duration of treatment and follow-up is 6 months. The symptoms most easily 
measured are the presence and severity of behavioural abnormalities. 
We introduce a new therapeutic approach to FXS, based on the hypothesis that an increase in 
free radical production and a deficit of vitamins are involved in the pathology and this often 
provokes severe comorbidity. Moreover, we take into account that current treatment protocols 
are frequently ineffective among young children and present important potential side effects. 
Thus, we propose the following: 
Main goal – to show that the combination of 10 mg/Kg/day tocopherol and 10 mg/Kg/day 
ascorbic acid reduces hyperactivity and behaviour abnormalities among patients aged 6–18 
years compared to placebo treatment. 
Secondary goals – to assess the safety of the treatment in terms of adverse or unexpected 
events; to describe metabolic changes resulting from the treatment, as revealed by blood 
measurements; and to measure the impact of this treatment on the quality of family and 
scholar life. 
2.1 Design 
2.1.1 Type of clinical trials 
Double blind, randomized clinical study, Phase II. 
The study began in December 2010 and is currently in progress. 
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2.1.2 Recruitment of patients 
The patients included are those diagnosed with FXS, according to molecular biology test, 
currently presenting symptoms. Paediatric Neurologists of the heathcare system were 
informed about the clinical trial in the Andalusian region, so patients could be referred to 
the sites where the study is being carried out. In order to maintain double blind conditions, 
the doctors responsible for patient evaluation derived each patient to the pharmacy 
department to be allocated to one of the two study groups, using a randomization program. 
Informed consent was obtained from parents or guardians, and none of the exclusion 
criteria were present. (See Figure 1). 
 
Fig. 1. Trial Flow Chart. 
2.2 Study subjects 
2.2.1 Patients 
Male patients diagnosed with FXS, aged 6–18 years, with clinical and behavioural symptoms 
of the disorder. 
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2.3 Selection criteria 
2.3.1 Criteria for inclusion 
- Male patients aged 6 to 18 years. This is the age range during which the natural course 
of the illness is most exacerbated. Before the age of 6, hyperactivity may not yet have 
appeared. After 18 years, behavioural symptoms tend to stabilize. 
- Informed consent of the child's parents or guardians, and reasoned agreement with 
patients older than 12. 
- Molecular diagnosis of FXS, according to molecular biology criteria of having more 
than 200 CGG and hypermethylation of the promoter region of the FMR1 gene. 
- Hyperactivity and behavioural symptoms of the disorder. 
2.3.2 Criteria for exclusion 
- Severe neurological condition not clinically controlled. 
- Unrelated neurological disorder. 
- Allergy to formula components (including excipients). 
2.3.3 Randomization, blinding and assignment to treatment group 
- Criteria set out above (age, diagnosis, consent). 
- Current pharmacological treatment for behavioural symptoms. 
- No contraindication due to the exclusion criteria. 
Patients who fulfil these criteria will be included, randomly, in one of the two groups of 
treatment. 
Randomization was centralized and performed after the patient group was studied at T0. A 
software program was used to ensure that allocation concealment is maintained within the 
pharmacy department at the hospital. The randomization code will be kept in the pharmacy 
department responsible for dispensing the corresponding medication. Randomization to 
either the treatment or the placebo group will only be performed when a patient, suffering 
FXS, is considered eligible to receive the medication included in this study (See figure 2). 
  Stratification         Randomization     Final 
        (age and medication)   (50% per group)  groups 
   
     Age    Medication 
         T 
         1     6-12    YES      C 
                   Treated 
    T     group (N=15) 
         2     6-12     NO       C   
Patients       
 (N=30)         T 
         3    13-18   YES       C                                    Control 
             group (N=15) 
    T 
         4    13-18    NO       C      
Fig. 2. Randomization Criteria for the Trial. Randomization by blocks and stratification for 
confusion factors (Age and concomitant medication). 
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2.3.4 Evaluations 
The clinical diagnosis of FXS will be confirmed, and the Conner’s score ascertained, so that 
the patient may be included in the study and any subsequent fall in the global score 
recorded (at t0, t1).  
2.3.5 Withdrawal of individual patients 
Patients may withdraw from the study at any time, for any reason and without suffering 
any sanction for doing so. The researcher-collaborator, after consulting with the principal 
investigator and the study coordinator, may also interrupt the treatment program if the fact 
of continuing this treatment, in his/her opinion, is prejudicial to the patients welfare. If a 
patient withdraws or is withdrawn from the study, follow-up to day 90 shall be continued 
whenever possible. 
2.4 Ethical criteria 
2.4.1 Applicable regulations 
The study was carried out in accordance with the principles of the Helsinki Declaration, 
specifically the EMEA/CPMP declaration on the use of the placebo in clinical trials, with 
respect to the revised Helsinki Declaration, and in accordance with the guidelines for Good 
Clinical Practice (CPMP/ICH/135/95 – 17 July 1996), as well as local regulations. 
2.4.2 Recruitment 
The study protocol was approved by the Ethics Committee of the Hospital Carlos Haya 
(Malaga, Spain). Implementation of the study began after the Spanish national healthcare 
authorities gave their official approval. Although patients were informed about the freedom 
of leaving the study at any time, we were interested in the recruitment of those offering the 
maximum probability of remaining within the study until its conclusion. 
2.4.3 Informed consent for minors 
After identifying candidate patients for inclusion in the clinical trial, the parents/guardians 
were provided with all available information and any complementary information that they 
could require, and they were given an information document so that their informed consent 
for the children participation in the trial was obtained. The signed form was given to the 
researcher when the child attended the clinic for the first basal evaluation (t0). 
2.4.4 Liability for injury 
According to Spanish Law regarding clinical trials, an insurance policy for civil liability was 
subscribed to cover any injuries that may arise from the performance of the study. 
2.5 Treatment details 
2.5.1 Dosage and administration of medication 
The medication used in the trial was administered orally, at the patients' home. The 
following medication was provided: Tocopherol acetate, 10 mg/kg/day, was administered 
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in two daily doses with a maximum of 600 mg/day. Ascorbic acid, 10 mg/kg/day, was 
administered in two daily doses with a maximum of 800 mg/day. 
2.5.2 Preparation and labelling of treatment procedures 
The medication for the trials was prepared, labelled and stored by the pharmaceutical 
service at the “Virgen de las Nieves” Hospital (Granada, Spain). The active principles of the 
treatment group were obtained via commercially available drugs. The placebo used was 
created in the hospital's pharmacy department, emulating the excipient and volume of the 
experimental medication (Colloidal Silica). Procedures for reducing the volume of 
medication per pack were implemented in accordance with ICH requirements. The study 
coordinator supervised all procedures applied in this respect. 
2.5.3 Other medication allowed 
The patients continued taking their usual medication to control symptoms or associated 
comorbid pathologies. Moreover, they continued receiving any pre-existing psychological or 
educational therapies. In addition, they continued taking any medication prescribed prior to 
the recruitment in the study. 
2.6 Specific methods 
2.6.1 Evaluation of effectiveness 
The clinical evaluation of the patients was carried out by applying the Conner's Parent 
Rating Scale-Revised: long Form [CPRS-R] (86), and the Conner's Teacher Rating Scale-
Revised: long Form [CTRS-R], (87).  
This scale was designed to study hyperactivity and has been validated for its use with 
children. The Conner’s score was applied by means of a structured questionnaire with 
multiple informants (generally, parents and teachers) to assess the child's behaviour over a 
period of at least three months. The translation into Spanish and its adaptation to local 
conditions were previously validated (88, 89).  
2.6.2 Adverse events 
Any adverse event notified spontaneously by the subject, or observed by the researcher or 
by the research team was recorded on the specific form designed for this purpose.  
2.6.3 Follow-up after occurrence of an adverse event 
All adverse events were observed until their remission or stabilization. Depending on the 
circumstances, this observation might necessitate evaluation by and/or referral to the 
patients’ GP or to a specialist. 
2.7 Procedures and control 
2.7.1 Selection of subjects 
Patients diagnosed with FXS were included in a preliminary "potential subjects" group. 
Before undertaking any selection activity, written informed consent, signed and dated, 
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was obtained from the parents or guardians. Patients’ parents were informed, before any 
action was taken, of the purposes of the study, and any doubts expressed were answered. 
It was highlighted that they have the unconditional right to withdraw from the study at 
any time.  
2.8 Data analysis 
2.8.1 Calculation of the statistical power; establishing the sample size; safety 
The sample size was established by means of a pilot scheme based on a phase II 
effectiveness trial, with 30 patients monitored over 3 months, for a level of significance of 
0.05 and a statistical power of 0.8, taking the least favourable case. On the basis of the 
prevalence of the FXS, 13 patients per group (26 in total) were needed. This sample size was 
then over-dimensioned to allow for a possible dropout rate of 10%, and so the minimum 
sample size was calculated to be n = 30 (15 patients per group). 
3. Results 
We have previously shown that NADPH-oxidase is highly activated in brain from Fmr1-
knockout mice compared to wild type (35). It is implicated in the production of free radicals, 
acting as a relevant source of ROS in brain tissue.  Furthermore, we have also demonstrated 
that chronic treatment with antioxidants was able to reduce the behavioural and learning 
hallmarks in the Fmr1-Knockout mouse (32, 90). In order to understand if an antioxidant 
combination of Ascorbic acid and Alpha-tocopherol, two well know antioxidants, is useful 
to reduce Fragile X patient’s symptoms we performed a pilot clinical trial in 30 patients 
affected with the Fragile X syndrome. 
Compared to the placebo group, those individuals receiving the antioxidant supplement 
showed an improvement in behaviour functioning measured by the Parent Conner’s Rating 
scales. Pill counts indicated good compliance with the regimen, and no serious adverse 
events attributed to the treatment were noted. 
The demographic characteristics of the study population are presented in Table I. The 
average age of the participants was 11,6 (SD 4,2) years, 12.1 (SD 3.4) in the treated group 
and 11.7(SD 4.8) in placebo group. Based upon a review of psychological testing records, 
80% of the controls and 75% of the treatment group were in the hyperactivity range 
according to the DSMIV criteria. In the placebo group, 45% were in the severe to profound 
range of hyperactivity, whereas 35% of the treatment group was in this category; a 
difference which was not statistically significant at the 0.05 level. Figure 1 displays a flow 
diagram that describes the participation from screening to the conclusion. Thirty 
participants initiated the trial, 15 of them taking antioxidant supplements and 15 taking a 
placebo. 100% of participants in both groups remained in the study at the 12 week study 
visit (t1).  
In the treatment group, among those participants with associated seizure disorder, 2 out of 
15 participants had at least one seizure prior to enrolling in the study and were taking 
anticonvulsant drugs. While in the placebo group none of the participants had a seizure 
before entering the study. Asthma, obsessive convulsive disorder and autistic features were 
present in the patients included in the trial (see table 1). 
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Patient Characteristics Active (n = 15) Placebo (n = 15) Total (n = 30) 
Age, years, M(SD)   12.1(3.4) 11.7(4.8) 11.6(4.2) 
Age groups, n (%)  
         6–12 years 
         13–18 years 
 
7(56) 
8(37) 
 
8(44) 
7(63) 
 
15 (50) 
15(50) 
Gender, n (%) 
         Male 
 
15(50) 
 
15(50) 
 
30(100) 
Weight M(SD) 53.2(6.6) 50.9(6.6) 52.1(4.6) 
Psycopharmacological treatment, n(%) 11(36,66) 11(36,66) 18 (60) 
Parent Conner’s Rating scales, M(SD) 
          DSM-IV Hyperactive/impulsive 
          DSM-IV Inattentive 
 
67.8(12.1) 
60.3(8.8) 
 
64.2(12.0) 
62.2(9.3) 
 
66.0(12.0) 
61.3(9.0) 
Teacher Conner’s Rating scales, M(SD)   
          DSM-IV Hyperactive/impulsive 
          DSM-IV Inattentive 
62.8(10.3) 
64.6(6.7) 
64.7(14.4) 
67.6(8.1) 
63.7(12.3) 
66.1(7.5) 
Associated conditions, n (%) 
          Epilepsy   
          Asthma  
          Autistic traits 
          Obsessive compulsive disorder 
 
2(6.6) 
2(6.6) 
2(6.6) 
0(0) 
 
0(0) 
0(0) 
2(6.6) 
1(3.3) 
 
2(6.6) 
2(6.6) 
4(13.2) 
1(3.3) 
Note: DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; M =Mean; SD 
=Standard deviation; n =number of patients; p = statistic significance; % = percentage. 
Table 1. Demographics of Sample 
According to the results of the Parent Conner’s Rating scales for the DSM-IV 
Hyperactive/impulsive subscale, this symptom was present in 22 participants. 70% (7 out of 
10) in the treated group and 16,6% (2 out of 12) in the placebo group significantly reduced 
this symptom after 12 weeks of antioxidant treatment (p<0.05). The reduction was mainly 
observed in the younger group of patients, 87,7 % significantly reduced hyperactive 
behaviour of those between 6 and 12 year old in the treated group (See table 2).  
 
Patient Characteristics n (Baseline) Active Placebo p 
Total 30 (11/15) (4/15) <0.05 
Age groups 
    6–12 years 
    13–18 years 
 
15 
15 
 
(7/8) 
(4/7) 
 
(1/8) 
(3/7) 
 
<0.05 
ns 
Parent Conner’s Rating scales M(SD) 
    DSM-IV Hyperactive/impulsive 
    DSM-IV Inattentive 
 
22 
21 
 
(7/10) 
(5/9) 
 
(2/12) 
(4/12) 
 
<0.05 
ns 
Teacher Conner’s Rating scales, M(SD) 
    DSM-IV Hyperactive/impulsive 
    DSM-IV Inattentive 
 
23 
26 
 
(5/12) 
(8/13) 
 
(2/11) 
(2/13) 
 
ns 
ns 
Note: DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; M =Mean; SD 
=Standard deviation; n =number of patients; p = statistic significance; % = percentage. 
Table 2. Patient Characteristics and Response Rates in Subgroups 
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4. Discussion 
FXS is considered to be a rare neurodevelopmental disease, although different rates of 
prevalence are being reported in current studies (2, 5). The condition is seldom diagnosed in 
Spain, due to unawareness of its existence and characteristics (5). Until very recently, FXS 
was only recognized as such for the most severe cases, in which there was an important 
degree of functional limitation or very evident autism. Few clinical trials have been carried 
out with children affected by FXS, probably due to its consideration of a rare disease, in 
addition to the normal difficulties in this kind of study and the special ethical and legal 
considerations to protect minors. Nevertheless, such studies are clearly needed (33). 
FMRP is involved in the regulation of proteins causing brain oxidative stress, so in the 
absence of FMRP there is hyperactivation of RAC1-GTPase dependent NADPH-oxidase 
signalling. These alterations lead to an excess of free radical production and then, when 
antioxidants are unable to counteract the production of free radicals, this fact at in the long 
term produces oxidative stress which is a crucial factor in the central nervous system that 
disrupts neuronal, astrocyte and microglia communication (36). Evidence of oxidative stress 
in FXS is manifested through high levels of oxidised proteins, lipid peroxidation end 
products, formation of protein-carbonyls and oxidative alteration of the glutathione system 
in the brain of the Fmr1-Knockout mouse model (32, 35, 90). 
Since 1983, it has been indicated that vitamins can improve Fragile X patients’ symptoms. 
The first vitamin used for the treatment of the FXS was folic acid, and several publications 
assessed it’s efficacy and safety (91-96).   
Two double-blind trials have assessed the safety and efficacy of L-Acetyl-Carnitine (LAC) in 
boys with FXS and an additional diagnosis of ADHD. Both of these trials were randomized 
placebo-controlled and used a parallel design. They also reported no significant side-effects 
in the LAC group (97,98).  
There are also enhanced, abnormal epileptic discharges consistent with an enhanced rate of 
clinical seizures in FXS patients and also auditory-dependent seizures in the mouse model. 
There are several studies regarding the use of tocopherol to control seizures in animal 
models and humans (99)  
A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted, 
and either 3 mg/day melatonin or placebo was given to participants for 2 weeks and then 
alternated for another 2 weeks. The results of this study support the efficacy and tolerability 
of melatonin treatment for sleep problems in children with FXS (100).  Melatonin is known 
to have antioxidant properties that can be involved in the effectiveness of this treatment. 
To assess antioxidant positive effects versus placebo, a one-way crossover study was 
selected due to the impossibility of abolishing a 'carry-over' of treatment effect from the first 
period of treatment to the next. A carry-over effect means that the observed difference 
between the treatments depends upon the order in which they were received; hence the 
estimated overall treatment effect will be affected (usually underestimated, leading to a bias 
towards the null) (101).   
Orally-administered antioxidants such as Tocopherol and ascorbic acid have been used as a 
nutritional supplement, and are considered safe even for children. Tocopherol is 
contraindicated in cases of vitamin K deficiency caused by malabsorption or anticoagulant 
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therapy. The FDA’s recommended daily dose is 10 mg/day, but the tolerable upper intake 
level is considered 300 mg/day (102). In our trial, we decided to use a maximum dose of 600 
mg/day as it was proven in many other previous studies to be safe and give a therapeutic 
dose (85).  
Vitamin E (alpha-tocopherol) is a liposoluble vitamin with a wide therapeutic margin. In 
clinical and pharmacological trials, it has been shown to have interesting properties, 
participating in oxidative deamination, transamination and decarboxylation; it also 
participates in the decarboxylation of glutamic acid to GABA, from DOPA to dopamine and 
from 5-hydroxytrytophan to serotonin. It presents anti-convulsant properties and seems to 
exercise a neuroprotective and antitoxic effect. It can be administered to children, and has 
been authorized for use to treat children with alterations in character, language and 
behaviour; learning difficulties; delayed learning to walk; convulsive illnesses; intoxication 
of the central nervous system; trembling; and Parkinson's disease. The dosage provided may 
vary widely, as renal elimination ensures its toxicity is minimal (101). 
The follow-up period of three months is based on previous trials and also considered a 
minimum period to improve symptoms such as behaviour and antioxidant status. We 
believe that if the patient enters the analysis with a Conner’s T-score higher than 55, it will 
be easier to identify significant differences, with the symptoms being controlled to a greater 
extent, and more quickly, among the experimental group than among the control group. 
The combined application of these measurement methods, namely the objectification of FXS 
behavioural symptoms will enable us to reach an objective judgment of the effectiveness 
and safety of the treatment being tested. 
In summary, treatment for FXS continues to present important shortcomings and further 
clinical trials are necessary in this respect, especially among children showing more severe 
symptoms. Our result demonstrates, for the first time, the efficacy of antioxidant 
combination to control behaviour in the fragile X patients showing moderate or severe 
hyperactivity.  
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